More on BLCO

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+16.7% Growth)
- Ratings (5.8 Score)
- Holders

Upcoming Events

- Earnings (10/28/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Bausch + Lomb Corporation (NY:BLCO)
Delayed: 17.43 +0.25 (1.46%)
Prev. Close $17.18  
Open$17.12 
52 Wk High$ 
52 Wk Low$ 
Day High$17.45 
Day Low$17.01 
P/E N/A  
EPS$ 
Volume426,369 

Friends, Peers and Foes (?): BHC, DC8, ALC IQV (more...)

Oct 13, 2026 06:10 AM Form 8-K Bausch & Lomb Corp For: Oct 11
Oct 12, 2026 06:46 AM Bausch + Lomb names Appio interim CEO as Saunders departs
Oct 12, 2026 06:45 AM Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Oct 8, 2026 08:04 AM RBC Capital on Bausch & Lomb Corp. (BLCO): 'Rx DED momentum drives estimates higher'
Oct 6, 2026 04:30 PM Bausch + Lomb eyes 2027 trial start for oral dry AMD drug
Oct 6, 2026 04:30 PM Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
Oct 6, 2026 04:25 PM Barclays Starts Bausch & Lomb Corp. (BLCO) at Overweight
Oct 5, 2026 07:30 AM Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
Sep 11, 2026 06:11 AM Bausch + Lomb gets EU approval for SeeLyra femtosecond laser
Sep 11, 2026 06:11 AM Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
View All Articles

Entities mentioned with BLCO

View All Entities